New Job Opportunity

September 11, 2025 | New Job Opportunity

Biocon Opens First U.S. Manufacturing Facility in New Jersey, Boosting Jobs & Innovation

Biocon Limited, an innovation-led global biopharmaceutical company, announced the inauguration of its first U.S. manufacturing facility in Cranbury, New Jersey, by its wholly owned subsidiary, Biocon Generics Inc (BGI). This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint. The Cranbury facility represents a strategic advancement for the Company's U.S. operations, enabling faster access to essential therapies, enhanced supply reliability and a stronger connection with partners and healthcare providers, ultimately benefitting patients across the United States. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, "Biocon's first U.S. FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are. Governor Phil Murphy's presence at the inauguration highlights the importance of Biocon's role in fostering innovation, creating job opportunities, and strengthening the U.S. healthcare ecosystem. This facility reflects our long-term commitment to deeper engagement with healthcare providers, innovators, and communities to build a healthier and equitable future." Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, "We were deeply honoured to have Governor Phil Murphy and our Chairperson, Kiran Mazumdar-Shaw, join us in marking this milestone of the Biocon Group's first manufacturing facility in the U.S. This strategic investment brings us closer to patients, healthcare providers, and partners in this important market. The proximity allows us to deliver our vertically integrated, high-quality medicines more efficiently to patients across the United States and other markets, ensuring supply chain resilience and enabling us to advance our mission of expanding access to affordable therapies worldwide." "We are incredibly grateful that Biocon has decided to open its first U.S. manufacturing facility in the Garden State," said Governor Murphy. "For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocon's global expansion and reinforces New Jersey's reputation as the medicine chest to the world."

September 08, 2025 | New Job Opportunity

Garonit Pharma Invests $46.1M in State-of-the-Art NY Facility

Garonit Pharmaceutical, Inc., a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County. With a $46.1 million investment, the facility will become the world’s largest chlorhexidine gluconate manufacturing operation, producing antiseptic products essential for surgical disinfection and infection prevention in hospitals worldwide. New York State is supporting this project with $3.8 million, including up to $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant. The project marks a major milestone in New York’s strategy to grow its life sciences sector and expand domestic pharmaceutical manufacturing. Empire State Development President, CEO, and Commissioner Hope Knight said, “Garonit Pharmaceutical’s expansion into New York reflects the confidence that global companies have in our state’s workforce, infrastructure, and innovation ecosystem. The Mid-Hudson region's strategic location, robust infrastructure, and proximity to world-class transportation networks make it an ideal location for advanced manufacturing operations. This project will generate long-term economic benefits and position the region for continued growth in the pharmaceutical sector.” Garonit Pharmaceutical Inc. Owner Rohit Garg said, ”As the U.S.-based owner of an API manufacturing company, I have long aspired to produce finished pharmaceutical products here in the United States. This achievement has been made possible through the invaluable support and collaboration of dedicated teams of The State of New York, Orange County, and City leaders of New Windsor.” Garonit Pharmaceutical Inc. Owner Nitin Garg said, “In designing our new manufacturing facility, we were thrilled to incorporate a dedicated technology research and development center in New Windsor, which will serve as a hub for formulating new FDA-regulated products. This milestone is strengthened by our collaboration with SUNY Orange, as we work together to develop programs that bridge operational excellence with advanced research and development.” MHREDC Co-Chair Dr. Marsha Gordon said, “The Garonit Pharmaceutical facility represents a transformative opportunity for Orange County and demonstrates the impact of strategic regional planning. This investment will create meaningful employment opportunities for our residents while advancing our region as a destination for pharmaceutical manufacturing. The comprehensive workforce development partnership with SUNY Orange ensures that local residents will be prepared to participate in this growing industry and benefit from the career opportunities it provides.”

September 08, 2025 | New Job Opportunity

Enzene Expands to U.S. with New Jersey Manufacturing Hub

Governor Phil Murphy officially inaugurated the state-of-the-art biomanufacturing facility of Enzene, a leading global continuously innovative development and manufacturing organization (CIDMO), marking a significant milestone in the expansion of global biotech capabilities in the United States. “When Enzene — one of India’s most promising biotechnological companies — decided to launch its very first U.S. manufacturing base, they knew there was nowhere better to do it than right here in New Jersey. Their decision reflects not only our state’s strength as a hub for global business and innovation, but also the deep cultural ties that bind New Jersey and India,” said Governor Phil Murphy. “This state-of-the-art facility represents the future of advanced manufacturing — ultimately creating hundreds of jobs and generating $50 million in investment. As Enzene expands its presence here in New Jersey, we remain committed to supporting the company as it builds the world-class manufacturing ecosystem of tomorrow.” “We are proud to bring our global expertise to the U.S. and contribute to the advancement of biopharmaceutical manufacturing,” added Himanshu Gadgil, Ph.D., CEO of Enzene. “Our first-to-market manufacturing technology is forging a new path in biologics manufacturing that will provide a cost-efficient, high yield, U.S.-based biomanufacturing solution for biopharmaceutical innovators, and complement our facilities in India to provide global supply solutions.” Sandeep Singh, Chairman of the Board at Enzene and Managing Director of Alkem Laboratories, added, “Enzene has demonstrated that it is committed to providing transformative innovations that can have a positive impact on biopharmaceutical development. In pioneering small-footprint, scalable biomanufacturing, Enzene is providing benefits in sustainability, cost, and ultimately to the global healthcare ecosystem. This latest step in the company’s strategic expansion plans extends Enzene’s commitment to providing equitable access to cost-effective manufacturing for early-stage biologics developers in the U.S. and beyond.” The opening ceremony was also attended by state and local officials, including the Mayor of Hopewell Township, Courtney Peters-Manning, First Lady of New Jersey, Tammy Murphy, and delegates from the offices of Senator Kim and Congresswoman Bonnie Watson Coleman.

September 05, 2025 | New Job Opportunity

Amgen’s New State-of-the-Art Center Set to Generate Jobs in California

Amgen announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology. Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. This investment includes over $5 billion in direct capital expenditures in the U.S. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing. "At Amgen, we're continuing to invest in the future of American science and innovation," said Robert A. Bradway, chairman and chief executive officer at Amgen. "This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health." The new center for science and innovation enhances the company's global network of sites, leveraging decades of operational expertise and technological advancements. Construction is expected to begin in Q3 2025 and create hundreds of U.S. jobs. Amgen has been headquartered in Thousand Oaks, California, part of the greater Los Angeles region, since the company's founding more than 45 years ago. The announcement builds on other recent investments from the company including a $900 million expansion of its manufacturing facility in Central Ohio and a $1 billion investment to build a second manufacturing plant in Holly Springs, North Carolina.

September 05, 2025 | New Job Opportunity

Gilead Expands Biologics Hub, Creating 3,000+ Jobs in California

Gilead Sciences celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities. It is part of Gilead’s planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling high-quality jobs, research, and domestic manufacturing. “This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.” The new facility will strengthen Gilead’s biologics capacity and capabilities, a central pillar of the company’s growth strategy. This investment builds on Gilead’s broader U.S. efforts to expand research and manufacturing, create more than 3,000 direct and indirect high-quality jobs, and advance equitable access to healthcare nationwide. “California is proud to be home to Gilead Sciences and its ongoing investment in innovation and jobs right here in Foster City,” said California Lieutenant Governor Eleni Kounalakis. “This new Technical Development Center is more than a milestone for Gilead; it’s a win for all who will benefit from its breakthroughs. It demonstrates that when we invest in domestic biomanufacturing, we strengthen supply chains, create thousands of good-paying jobs, and keep America at the forefront of life-saving innovation.” This groundbreaking is part of a broader expansion at Gilead’s Foster City headquarters. In addition to the NTDC, the company is currently developing two other state-of-the-art facilities: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead’s strong history of U.S. investment, with more than $15 billion over the last decade, and reinforce the company’s role as a major contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for patients. Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead’s role as a U.S.-based biopharma leader in improving human health globally.

September 03, 2025 | New Job Opportunity

$220M Investment to Turn Delpharm’s Boucherville Site into Pharma Hub

Delpharm is proud to announce a major milestone in the modernization of its Boucherville facility, made possible by a $60 million government contribution unveiled today by Economy, Innovation and Energy Minister Christine Fréchette, alongside Health Minister Christian Dubé. This contribution adds to the previously confirmed $60 million investment from the federal government, announced last March, along with $100 million in private capital, bringing the total to $220 million. By 2031, this investment will transform Delpharm’s Boucherville site into a worldclass pharmaceutical facility. “I’m proud to announce this $60-million investment in a company that contributes to the prosperity of Québec’s life sciences sector. By partnering with Delpharm and investing in its success, our government is ensuring our supply chains are strengthened and demand from the hospital market is sustained. This partnership will positively. “Delpharm is a strategic supplier to Québec’s healthcare network, which makes heavy use of the products designed by the Boucherville-based company. Its manufacturing site is the largest sterile injectable drug production facility in Canada, supplying a significant portion to the Québec and Canadian markets. This investment will allow Delpharm to bolster its innovation and production capacity. Congratulations to Delpharm on this promising expansion!” Christian Dubé, Minister of Health“We would like to acknowledge the commitment of the Ministry of Economy, Innovation and Energy, a key partner in strengthening Québec’s pharmaceutical autonomy. We also wish to recognize our long-standing partner Sandoz, with whom we have renewed a 10-year contract to produce generic hospital medicines. This agreement guarantees patients in Québec and across Canada a local, stable, and reliable supply.” Tangible benefits for QuébecThanks to the support of the provincial government, this project will generate tangible benefits for Québec’s economy and society:• More than 500 specialized jobs preserved;• $100 million injected into the local economy each year through salaries and purchases from Québec suppliers.Delpharm will repay over time $105 of the $120 million in government support, in addition to dividends to be paid by the company to the Québec government.

September 03, 2025 | New Job Opportunity

Quasar Medical Acquires Nordson Units, Unlocking 200+ New Job Opportunities

Quasar Medical, a global leader in manufacturing interventional and minimally invasive medical devices, announced the completion of its acquisition of Nordson Corporation's design & development contract manufacturing businesses in Galway, Ireland, and Tecate, Mexico. Quasar's evolution into a fully integrated Contract Development and Manufacturing Organization (CDMO) marks a transformative step, offering customers concept-to-commercialization solutions worldwide. The company is expanding its workforce by nearly 200 employees, including expert development engineers and technicians, creating new opportunities for advancement. "This strategic acquisition marks an exciting new chapter for Quasar and the customers we serve," said Alex Wallstein, CEO of Quasar Medical. "By combining our manufacturing excellence with the world-class design, development, and assembly expertise of the Galway and Tecate teams, we are expanding our global reach, moving closer to our customers and creating a truly global CDMO platform. Together, we will partner with customers and suppliers earlier in the product lifecycle, delivering innovation, scalability, and speed to market at every stage." With this acquisition, Quasar strengthens its global presence with two FDA-registered, ISO 13485-certified facilities situated in key MedTech regions—Europe and North America—improving customer proximity and access. Galway, Ireland, now serves as an innovation hub for design & development for extrusions, braiding, balloons, and complex catheters, providing advanced support in product design, prototyping, and clinical innovation. Tecate, Mexico, adds cost-effective, high-volume manufacturing capabilities, facilitating a smoother transition from development to commercialization. "This is a pivotal milestone that positions Quasar as a strategic partner to our customers — not just a manufacturer," said Aviel Bohnik, COO of Quasar Medical. "With the addition of Galway and Tecate, we now offer a truly differentiated platform that combines upstream innovation, downstream scalability, and our unsurpassed ramp-up capabilities—accelerating time to market for our customers. These new sites strengthen our ability to deliver high-value solutions through vertical integration, customer collaboration, and operational excellence across key regions."

August 28, 2025 | New Job Opportunity

Genentech to Create 1,900 Jobs with New North Carolina Facility

Genentech, a member of the Roche Group broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 700,000-square-foot facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity. The event was attended by federal, state and local officials, including U.S. Rep. Deborah Ross, North Carolina Gov. Josh Stein, State Sec. of Commerce Lee Lilley, State Sens. Sydney Batch and Lisa Grafstein, State Rep. Erin Paré, Wake County Commissioner Cheryl Stallings and Holly Springs Mayor Sean Mayefskie. The project will add more than 400 local manufacturing jobs when the site is operational and more than 1,500 construction jobs during the development phase. Genentech’s initial investment in North Carolina is estimated at more than $700 million, part of a larger $50 billion commitment to President Trump’s initiatives to invest in U.S. manufacturing, infrastructure and R&D. The company selected Holly Springs, a growing hub for biopharmaceutical innovation, for its highly skilled local workforce, strong academic institutions and proximity to other leading life science companies in the Raleigh-Durham area. The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The future facility will increase production capacity for the company’s manufacturing network, while enhancing supply chain resilience through a high-volume, high-efficiency yet sustainable design. The 100-acre lot includes space for future expansion. Genentech CEO Ashley Magargee: “We are proud to break ground on our new manufacturing site in Holly Springs, North Carolina, with its world-class biotech talent, top research institutions and a robust infrastructure that will enable our growth for years to come. With this step, we are taking action to deliver more life-changing medicines to patients faster, contribute to the local economy, and bolster manufacturing and innovation in the U.S.,” Magargee said. “We are supportive of President Trump's goal to bring more pharmaceutical manufacturing to the United States and appreciate the work that Commerce Secretary Lutnick and the Department of Commerce's U.S. Investment Accelerator are doing to remove regulatory barriers that cause delays in establishing manufacturing sites in the U.S. We also thank the North Carolina, Wake County and Holly Springs officials for their partnership. Their warm welcome and leadership in the life sciences bodes well for great things to come for our company, your communities, and, ultimately, for patients.” U.S. Rep. Deborah Ross, 2nd North Carolina Congressional District: “This groundbreaking is a milestone for our community and for North Carolina’s growing role in the biotech economy. Investments like this one mean good-paying jobs for our residents, expanded opportunities for workers with a range of skills and education, and continued growth for the Research Triangle’s innovation ecosystem. I look forward to working with Genentech to ensure this facility helps our region to thrive for decades to come.”

August 22, 2025 | New Job Opportunity

Johnson & Johnson to Create 500 Jobs with $2B Holly Springs Facility

Johnson & Johnson, healthcare’s leading, most comprehensive innovation powerhouse, announced it will increase its presence in North Carolina with a 160,000+ square foot dedicated manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment to FUJIFILM over the next 10 years will expand the Company’s U.S. manufacturing capacity and create approximately 120 new jobs in North Carolina. In the coming months, the Company also intends to share the plans for additional advanced manufacturing facilities in the U.S. as well as the expansion of current U.S. sites. These plans reinforce Johnson & Johnson’s leadership in delivering cutting-edge healthcare solutions and will enable the Company to manufacture the vast majority of our advanced medicines in the U.S. to meet the needs of U.S. patients. “Johnson & Johnson has more manufacturing facilities in the U.S. than in any other country, and we continue to strengthen our presence here,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With the recent signing of the One Big Beautiful Bill Act, we continue to expand our investment in the U.S. to lead the next era of healthcare innovation.” In March, the Company announced it will invest $55 billion to support U.S. manufacturing, research and development, and technology investments over the next four years. Progress continues in the construction of the Wilson, North Carolina facility, which will employ more than 500 people when fully operational and create approximately 5,000 construction jobs during the site development. Other investments include extensive R&D infrastructure aimed at developing lifesaving and life-changing treatments in areas such as oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery. Using the facility at the state-of-the-art FUJIFILM site in Holly Springs will allow the Company to further expand its manufacturing capacity in the U.S., and across the U.S., the Company’s investments will support thousands of jobs.

August 22, 2025 | New Job Opportunity

Thermo Fisher's New Site to Add 100 Jobs in Biotech Manufacturing

Thermo Fisher Scientific Inc., the world leader in serving science, announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C. “As a global leader in life sciences manufacturing, we’re proud to serve as a growth engine for the American economy and provide our customers with a strong and agile supply chain that enables them to advance human health,” said Erica Hirsch, president, laboratory chemicals, Thermo Fisher Scientific. “The opening of our Mebane site is a testament to our larger strategy to strengthen our manufacturing capabilities in the U.S. and support continued innovation and expanded growth in North Carolina, building on the strong foundation we’ve already established in this state.” Pipette tips are critical tools for research and diagnostics, enabling precise liquid handling in high-volume applications such as disease studies and diagnostic testing. Thermo Fisher manufactures its tips with high-quality materials and strict quality controls to ensure accuracy, reduce contamination, and deliver consistent performance. The new Mebane site is built for efficiency, with advanced automation that produces 96 tips every 12 seconds and 5,000 finished assemblies per hour. Designed for seamless operations, it also features automated packaging and shipping to meet growing customer demand. “Thermo Fisher Scientific’s new facility strengthens North Carolina’s leadership in the biotech sector and strengthens our domestic supply chain,” said Governor Josh Stein. “I am proud to welcome this global company to Mebane as it expands its North Carolina presence with 100 good-paying jobs.” The new Mebane site has already hired 40 people and is expected to add 50 jobs in manufacturing, engineering and business operations. Thermo Fisher currently employs approximately 7,800 colleagues across 13 sites in N.C., including a center of excellence for laboratory equipment in Asheville, three life sciences [and] manufacturing sites in Durham, pharmaceutical manufacturing sites in Greenville and High Point, and a Raleigh distribution center.

Page 1 of 42

Featured Recruiters